Comparative Effectiveness of a Second Tumor Necrosis Factor Inhibitor Versus a Non–Tumor Necrosis Factor Biologic in the Treatment of Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis
Main finding · cJADAS10 ID (≤2.5)Result — go to the resultAdjusted odds ratio 1.23 95% CI 0.47–3.20Authors' conclusion
Most patients with pJIA started receiving TNFi rather than non-TNFi as their second biologic, and there were no differences in disease activity at six months.
Study context
- Population
- Patients with pJIA starting a second biologic after a first tumor necrosis factor inhibitor (TNFi), no active uveitis on index date, CARRA Registry
- Participants
- 216 patients
- Exposure
- Second TNFi vs non-TNFi biologic after discontinuation of a first TNFi
- TNFin = 183
- Non-TNFin = 33reference
- Outcome
- cJADAS10 inactive disease (≤2.5) and minimal disease activity (≤5)
- Follow-up
- Six months
Methodological detailsChildhood Arthritis and Rheumatology Research Alliance Registry, multiple imputation, propensity score quintiles
- Childhood Arthritis and Rheumatology Research Alliance Registry
- Multiple imputation
- Propensity score quintiles
Main finding
cJADAS10 inactive disease (ID) (≤2.5)
Adjusted odds ratio
1.23
95% CI 0.47–3.20
By group
TNFivs Non-TNFi
aOR 1.23 (95% CI 0.47–3.20)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | TNFi | Non-TNFi | aOR (95% CI) | |
|---|---|---|---|---|
| At least cJADAS10 MiDA (≤5) · six months | 43% | 39% | 1.11 (0.47–2.62) | |
| 0.20.5125Adjusted odds ratio (log scale) |
Original publication
Comparative Effectiveness of a Second Tumor Necrosis Factor Inhibitor Versus a Non–Tumor Necrosis Factor Biologic in the Treatment of Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis. Arthritis Care Res (Hoboken). Published 7 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →